Direct Agglutination Test - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512241494

Publication Date:

December 11, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

The Direct Agglutination Test (DAT) is a diagnostic test used in immunology to detect antibodies or antigens in a patient's sample, typically blood or other body fluids. It is commonly used to diagnose and monitor infectious diseases caused by certain pathogens, especially those that induce antibody production.

The global market for Direct Agglutination Test was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Direct Agglutination Test was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Direct Agglutination Test was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Direct Agglutination Test was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Direct Agglutination Test include Atlas Medical GmbH, Thermo Fisher Scientific, Bio-Rad, HiMedia, Pro Lab, Arlington Scientific, Hardy Diagnostics, Liofilchem S.r.l and Biotec, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Direct Agglutination Test, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Direct Agglutination Test by region & country, by Type, and by Application.
The Direct Agglutination Test market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct Agglutination Test.
麻豆原创 Segmentation
By Company
Atlas Medical GmbH
Thermo Fisher Scientific
Bio-Rad
HiMedia
Pro Lab
Arlington Scientific
Hardy Diagnostics
Liofilchem S.r.l
Biotec
Segment by Type:
Blood
Urine
Escherichia Coli
Others
Segment by Application
Clinics
Hospital
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Direct Agglutination Test manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Direct Agglutination Test in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Direct Agglutination Test in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Direct Agglutination Test Product Introduction
1.2 Global Direct Agglutination Test 麻豆原创 Size Forecast
1.3 Direct Agglutination Test 麻豆原创 Trends & Drivers
1.3.1 Direct Agglutination Test Industry Trends
1.3.2 Direct Agglutination Test 麻豆原创 Drivers & Opportunity
1.3.3 Direct Agglutination Test 麻豆原创 Challenges
1.3.4 Direct Agglutination Test 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Direct Agglutination Test Players Revenue Ranking (2023)
2.2 Global Direct Agglutination Test Revenue by Company (2019-2024)
2.3 Key Companies Direct Agglutination Test Manufacturing Base Distribution and Headquarters
2.4 Key Companies Direct Agglutination Test Product Offered
2.5 Key Companies Time to Begin Mass Production of Direct Agglutination Test
2.6 Direct Agglutination Test 麻豆原创 Competitive Analysis
2.6.1 Direct Agglutination Test 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Direct Agglutination Test Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct Agglutination Test as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Blood
3.1.2 Urine
3.1.3 Escherichia Coli
3.1.4 Others
3.2 Global Direct Agglutination Test Sales Value by Type
3.2.1 Global Direct Agglutination Test Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Direct Agglutination Test Sales Value, by Type (2019-2030)
3.2.3 Global Direct Agglutination Test Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinics
4.1.2 Hospital
4.1.3 Other
4.2 Global Direct Agglutination Test Sales Value by Application
4.2.1 Global Direct Agglutination Test Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Direct Agglutination Test Sales Value, by Application (2019-2030)
4.2.3 Global Direct Agglutination Test Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Direct Agglutination Test Sales Value by Region
5.1.1 Global Direct Agglutination Test Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Direct Agglutination Test Sales Value by Region (2019-2024)
5.1.3 Global Direct Agglutination Test Sales Value by Region (2025-2030)
5.1.4 Global Direct Agglutination Test Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Direct Agglutination Test Sales Value, 2019-2030
5.2.2 North America Direct Agglutination Test Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Direct Agglutination Test Sales Value, 2019-2030
5.3.2 Europe Direct Agglutination Test Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Direct Agglutination Test Sales Value, 2019-2030
5.4.2 Asia Pacific Direct Agglutination Test Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Direct Agglutination Test Sales Value, 2019-2030
5.5.2 South America Direct Agglutination Test Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Direct Agglutination Test Sales Value, 2019-2030
5.6.2 Middle East & Africa Direct Agglutination Test Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Direct Agglutination Test Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Direct Agglutination Test Sales Value
6.3 United States
6.3.1 United States Direct Agglutination Test Sales Value, 2019-2030
6.3.2 United States Direct Agglutination Test Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Direct Agglutination Test Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Direct Agglutination Test Sales Value, 2019-2030
6.4.2 Europe Direct Agglutination Test Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Direct Agglutination Test Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Direct Agglutination Test Sales Value, 2019-2030
6.5.2 China Direct Agglutination Test Sales Value by Type (%), 2023 VS 2030
6.5.3 China Direct Agglutination Test Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Direct Agglutination Test Sales Value, 2019-2030
6.6.2 Japan Direct Agglutination Test Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Direct Agglutination Test Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Direct Agglutination Test Sales Value, 2019-2030
6.7.2 South Korea Direct Agglutination Test Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Direct Agglutination Test Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Direct Agglutination Test Sales Value, 2019-2030
6.8.2 Southeast Asia Direct Agglutination Test Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Direct Agglutination Test Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Direct Agglutination Test Sales Value, 2019-2030
6.9.2 India Direct Agglutination Test Sales Value by Type (%), 2023 VS 2030
6.9.3 India Direct Agglutination Test Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Atlas Medical GmbH
7.1.1 Atlas Medical GmbH Profile
7.1.2 Atlas Medical GmbH Main Business
7.1.3 Atlas Medical GmbH Direct Agglutination Test Products, Services and Solutions
7.1.4 Atlas Medical GmbH Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.1.5 Atlas Medical GmbH Recent Developments
7.2 Thermo Fisher Scientific
7.2.1 Thermo Fisher Scientific Profile
7.2.2 Thermo Fisher Scientific Main Business
7.2.3 Thermo Fisher Scientific Direct Agglutination Test Products, Services and Solutions
7.2.4 Thermo Fisher Scientific Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.2.5 Thermo Fisher Scientific Recent Developments
7.3 Bio-Rad
7.3.1 Bio-Rad Profile
7.3.2 Bio-Rad Main Business
7.3.3 Bio-Rad Direct Agglutination Test Products, Services and Solutions
7.3.4 Bio-Rad Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.3.5 HiMedia Recent Developments
7.4 HiMedia
7.4.1 HiMedia Profile
7.4.2 HiMedia Main Business
7.4.3 HiMedia Direct Agglutination Test Products, Services and Solutions
7.4.4 HiMedia Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.4.5 HiMedia Recent Developments
7.5 Pro Lab
7.5.1 Pro Lab Profile
7.5.2 Pro Lab Main Business
7.5.3 Pro Lab Direct Agglutination Test Products, Services and Solutions
7.5.4 Pro Lab Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.5.5 Pro Lab Recent Developments
7.6 Arlington Scientific
7.6.1 Arlington Scientific Profile
7.6.2 Arlington Scientific Main Business
7.6.3 Arlington Scientific Direct Agglutination Test Products, Services and Solutions
7.6.4 Arlington Scientific Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.6.5 Arlington Scientific Recent Developments
7.7 Hardy Diagnostics
7.7.1 Hardy Diagnostics Profile
7.7.2 Hardy Diagnostics Main Business
7.7.3 Hardy Diagnostics Direct Agglutination Test Products, Services and Solutions
7.7.4 Hardy Diagnostics Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.7.5 Hardy Diagnostics Recent Developments
7.8 Liofilchem S.r.l
7.8.1 Liofilchem S.r.l Profile
7.8.2 Liofilchem S.r.l Main Business
7.8.3 Liofilchem S.r.l Direct Agglutination Test Products, Services and Solutions
7.8.4 Liofilchem S.r.l Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.8.5 Liofilchem S.r.l Recent Developments
7.9 Biotec
7.9.1 Biotec Profile
7.9.2 Biotec Main Business
7.9.3 Biotec Direct Agglutination Test Products, Services and Solutions
7.9.4 Biotec Direct Agglutination Test Revenue (US$ Million) & (2019-2024)
7.9.5 Biotec Recent Developments
8 Industry Chain Analysis
8.1 Direct Agglutination Test Industrial Chain
8.2 Direct Agglutination Test Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Direct Agglutination Test Sales Model
8.5.2 Sales Channel
8.5.3 Direct Agglutination Test Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Atlas Medical GmbH
Thermo Fisher Scientific
Bio-Rad
HiMedia
Pro Lab
Arlington Scientific
Hardy Diagnostics
Liofilchem S.r.l
Biotec

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.